An AI tool that reads a woman’s existing mammogram and estimates her five-year risk of developing breast cancer is now available nationwide without a doctor’s referral, after Boston-based Clairity launched its Clairity Breast™ platform through direct-to-consumer lab-testing company Everlywell on October 1, 2026. The move, examined in depth by STAT News health tech correspondent Katie Palmer in an October 8, 2026 feature, marks one of the first times an FDA-authorized diagnostic AI model has skipped the traditional path through physicians and insurers entirely.
What the AI Actually Does
Clairity Breast analyzes a patient’s existing screening mammogram — the same image already sitting in her medical record — and looks for subtle patterns the company says are invisible to the human eye. Rather than detecting a tumor that already exists, the tool estimates the likelihood that cancer will develop over the following five years, positioning it as a risk-prediction tool rather than a diagnostic one. According to Clairity’s own research page, the company describes it as the first FDA-authorized, image-based artificial intelligence tool for predicting future breast cancer risk, a claim first circulated via a GlobeNewswire release on February 23, 2026.
From Hospital Pilot to Home Delivery
Clairity Breast didn’t start as a consumer product. Beth Israel Deaconess Medical Center delivered the tool’s first clinical risk score in a hospital setting in February 2026, and the American cancer guideline group NCCN updated its guidelines on April 14, 2026 to incorporate AI-based five-year risk assessment starting at age 35. The shift to Everlywell on October 1 changes the distribution model substantially: now any woman with a qualifying screening mammogram from the past 12 months can order an assessment directly, with results reviewed by a licensed provider before being returned to the patient. Everlywell CEO Julia Cheek has pitched the company’s broader mission around giving consumers faster access to clinical-grade testing without waiting on the traditional referral pipeline.
The People Behind the Technology
Clairity was founded by Dr. Connie Lehman, a professor of radiology at Harvard Medical School and a longtime breast imaging researcher, who serves as founder and CEO. Dr. Dorraya El-Ashry, chief scientific officer of the Breast Cancer Research Foundation (BCRF), has been quoted in press coverage discussing the broader shift toward risk-based breast cancer screening, including research from Lehman and colleagues published in the journal Radiology showing that AI-detected risk signals can change over time, producing what the company describes as a dynamic risk score rather than a fixed one.
Why Going Direct-to-Consumer Is Controversial
STAT framed its coverage of the launch as part of a series called “Paying for AI,” which examines how new clinical AI tools affect health care affordability and long-term patient outcomes — a framing that signals skepticism as much as excitement. Bypassing physicians and insurers solves a real access problem: getting a novel risk-prediction tool through hospital credentialing committees and insurance coverage decisions can take years, and Clairity’s leadership has suggested that waiting for that slow process would have delayed benefit to patients unnecessarily. But critics of the direct-to-consumer model for medical AI have long warned that patients receiving an elevated risk score outside a clinical relationship may struggle to interpret what it means, may face anxiety without adequate counseling, or may pursue unnecessary follow-up imaging and biopsies without a treating physician coordinating next steps. The model also raises affordability questions: unlike a mammogram itself, a consumer-paid AI risk assessment isn’t necessarily covered by insurance, meaning the women most likely to benefit from early risk stratification may not be the ones who can easily pay out of pocket.
How It Fits a Bigger Shift in Breast Screening
The Clairity launch arrives amid a broader move within breast imaging away from one-size-fits-all screening schedules and toward individualized, risk-based approaches — the same shift reflected in NCCN’s April guideline update. Proponents argue that identifying high-risk women years before a cancer would otherwise be caught allows for earlier surveillance, preventive counseling, or risk-reducing medication, potentially catching cancers at a more treatable stage. The approach echoes other AI risk-prediction models like MIT’s Mirai, which Lehman has also been involved with, suggesting Clairity is as much a continuation of years of breast-imaging AI research as it is a sudden commercial leap.
What’s Next
With the nationwide Everlywell rollout barely two weeks old as of this writing, the real test will be uptake and outcomes data: how many women order the assessment, how primary care physicians respond to patients arriving with an AI-generated risk score they didn’t initiate, and whether insurers eventually move to cover the service as adoption grows. Clairity’s bet is that putting the tool directly in patients’ hands will accelerate validation and demand faster than the traditional hospital-by-hospital rollout could. Whether regulators, physician groups, and insurers follow that lead — or push back on diagnostic AI reaching patients without a clinician in the loop — will likely shape how the next wave of consumer-facing diagnostic AI tools come to market.
Photo: Timur Weber / PEXELS via Pexels
